Valneva SE
LB6V
Lyme disease
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on LB6V for Lyme disease is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 6-K
verified 13h ago
“Pfizer is planning submissions to regulatory authorities.”